A mixed vaccination of first AstraZeneca and then a Pfizer Covid-19 shot boosted neutralizing antibody levels by six times compared with two AstraZeneca doses, a study from South Korea showed.
People who received the one-dose Johnson & Johnson Covid-19 vaccine may need a booster shot to fend off some of the worrisome coronavirus variants now spreading worldwide, a study suggests.
Sinopharm’s Covid-19 vaccine elicited weaker antibody responses against the Delta variant, based on the first published study of its effect against the more contagious version.
The U.S. Food and Drug Administration granted approval to Octapharma USA for Octagam 10% [Immune Globulin Intravenous (Human)], the first intravenous immunoglobulin to be indicated for the treatment of adult dermatomyositis, a rare immune-mediated inflammatory disease.
Scientists are working on a benchmark for Covid-19 vaccine efficacy that would allow drugmakers to conduct smaller, speedier human trials to get them to market and address a huge global vaccine shortage.
Data from a mid-stage clinical study of an experimental vaccine candidate developed by Affinivax and Astellas Pharma for Streptococcus pneumoniae shows ASP3772 is well tolerated and generated an antibody response against the deadly bacterial infection.
A potential Covid-19 vaccine developed by a subsidiary of China’s Livzon Pharmaceutical Group Inc. appeared safe and able to elicit antibodies in healthy adults in a mid-stage clinical trial, Chinese researchers said.
GlaxoSmithKline Plc and U.S. firm Alector Inc. will together develop antibody-based treatments for Parkinson’s, Alzheimer’s and other similar diseases in a deal worth up to $2.2 billion, the drugmakers said on July 2.
The highly transmissible Delta variant of SARS-CoV-2, first identified in India, has become the most prevalent variant among new Covid-19 cases in the United States, according to California-based genomics company Helix.
With an $850 million investment from parent company Fujifilm Corporation, Fujifilm Diosynth Biotechnologies is expanding the company’s manufacturing capabilities to support an increased capacity for biologics and gene therapies.